Greenwich LifeSciences Inc Dossier
Financial Snapshot
Revenue, profitability, returns, debt, and capital allocation
Revenue $0TTM through 30 Jun 2026
Net Income -$22.5MTTM through 30 Jun 2026
Free Cash Flow -$12.5MTTM through 30 Jun 2026
Margins
| Current |
|---|
Balance Sheet Health
Debt / Equity0.00x
Current Ratio1.06x
Net Debt-$6.2Mnet cash position
Cash & Equivalents$6.2M
Quality Metrics
Altman Z-Score6.53
Piotroski F-Score1 / 9
Earnings-Beat Rate25.0%
Multi-Year Trend
Diluted EPS-$1.59TTMFY2025: $-1.43
Dividend
No dividend
Capital Allocation
R&D Spend$20.3M
Segment Performance
| Segment | Revenue | YoY | Outlook |
|---|---|---|---|
| Immunotherapy Development | $0 | View detailsThe company expects to continue incurring significant operating losses for the foreseeable future as it expands clinical trial sites and patient enrollment in Europe and the US. |
Filing Detail Members
This section is available to registered members. Create a free account or sign in to unlock the full breakdown.